Two molecules against KRAS from a hybrid AI and quantum process
A process combining quantum and classical computing with Chemistry42 selected 15 candidates; two showed activity against mutated KRAS variants in living cells. Published in Nature Biotechnology, this is a proof of principle, with no significant quantum advantage or demonstrated superiority over compounds obtained by classical methods.
Technology: Chemistry42 and hybrid quantum-classical models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Fifteen candidates from the hybrid process were tested in the lab, and two strongly targeted mutated KRAS variants in living cells.
- Still unknown: The source states it is a proof-of-principle study with no significant quantum advantage and no demonstrated superiority over classically designed molecules.
- AI role: Generative AI (Chemistry42) and a quantum-classical process designed molecules, narrowed to 15 candidates.
Evidence sources: https://www.utoronto.ca/news/ai-quantum-computing-used-target-undruggable-cancer-protein
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 125 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.